Novo Nordisk A/S $NVO Shares Bought by Salem Investment Counselors Inc.

Salem Investment Counselors Inc. lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 90.3% during the third quarter, Holdings Channel.com reports. The firm owned 117,692 shares of the company’s stock after purchasing an additional 55,853 shares during the period. Salem Investment Counselors Inc.’s holdings in Novo Nordisk A/S were worth $4,462,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Sax Wealth Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 3.4% during the third quarter. Sax Wealth Advisors LLC now owns 22,631 shares of the company’s stock valued at $858,000 after buying an additional 738 shares during the last quarter. Burkett Asset Management Ltd increased its position in shares of Novo Nordisk A/S by 1.3% during the third quarter. Burkett Asset Management Ltd now owns 41,646 shares of the company’s stock worth $1,579,000 after acquiring an additional 515 shares in the last quarter. Gallagher Capital Advisors LLC increased its position in shares of Novo Nordisk A/S by 13.8% during the third quarter. Gallagher Capital Advisors LLC now owns 7,085 shares of the company’s stock worth $269,000 after acquiring an additional 861 shares in the last quarter. Atlas Brown Inc. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth about $279,000. Finally, Avaii Wealth Management LLC raised its holdings in shares of Novo Nordisk A/S by 20.7% in the 3rd quarter. Avaii Wealth Management LLC now owns 15,751 shares of the company’s stock worth $588,000 after acquiring an additional 2,704 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk is continuing its share-repurchase program of up to DKK 15 billion over 12 months. Buybacks can support earnings per share and provide some demand for the shares, although the program is unlikely to offset broader concerns about growth. Novo Nordisk reports DKK 15 billion buyback program update Novo Nordisk share repurchase programme
• Neutral Sentiment: Analyst commentary highlights a trade-off for investors: Novo Nordisk has strong exposure to the expanding obesity and diabetes-treatment markets, but its valuation, revenue concentration and dependence on the product pipeline remain important risks. The comparison with AbbVie underscores that both companies face material, though different, challenges. AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
• Negative Sentiment: Investors are increasingly questioning whether Novo Nordisk’s pipeline can deliver enough growth to offset slowing visibility in its core franchise. Intensifying competition from Eli Lilly, pricing pressure and concerns about near-term demand are weighing on the shares. Novo Nordisk’s Pipeline Promise Meets a Sobering Reality Check Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $3.29 from $3.43 and its FY2027 forecast to $3.25 from $3.32, both below the roughly $3.53 current consensus estimate. The downward revisions reinforce concerns about earnings momentum. Novo Nordisk analyst earnings estimates
• Negative Sentiment: Recent market coverage attributes the underperformance versus the broader market to the combination of Eli Lilly competition, pricing pressure and limited near-term growth catalysts. Why Novo Nordisk dipped more than the broader market

Novo Nordisk A/S Price Performance

NVO opened at $38.03 on Wednesday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. The company has a market capitalization of $169.83 billion, a price-to-earnings ratio of 9.60, a P/E/G ratio of 1.31 and a beta of 0.76. The firm’s fifty day moving average price is $43.13 and its two-hundred day moving average price is $43.90.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were given a $0.5786 dividend. This represents a yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. This is a negative change from Novo Nordisk A/S’s previous dividend of $1.2751. Novo Nordisk A/S’s payout ratio is currently 20.05%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on NVO shares. Barclays reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 7th. Jefferies Financial Group reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, September 29th. Berenberg Bank restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Finally, Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Five analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $59.44.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.